Trial results

$TRDA — ENTR-601-45

Entrada Therapeutics, Inc. (TRDA) ENTR-601-45: trial results in Duchenne muscular dystrophy (DMD), 2027.

Research by Catalyst Intel

The catalyst

"-- ELEVATE-45-201 Cohort 2 enrollment is complete and the Company is on track to report data at the increased dose of 10 mg/kg in the first half of 2027 --"

— Entrada Therapeutics, 8-K filed 2026-10-14 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

TRDA-ENTR60145-2026

Company

Entrada Therapeutics, Inc.

Kind

Trial results

Indication

Duchenne muscular dystrophy (DMD)

Window

2027-01-01 – 2027-06-30

Status

dropped

The bar

No bar has been published for this event yet.

Verdicts

No verdict has been published for this event yet.